Dr Reddy's inks pact with Citius Pharma to sell all rights to anti-cancer agent E7777

Dr Reddy's will receive $ 40 million upfront upon the closing of the transaction, followed by approval milestone payment of up to $40 million related to the cutaneous T-cell lymphoma indication approval and up to $70 million for additional indication approvals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/38I4qoW
via IFTTT